BMS-986353

BIOLOGICAL2 trials

Sponsors

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Conditions

Autoimmune Hemolytic AnemiaChronic Immune ThrombocytopeniaSystemic Sclerosis

Phase 2

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

Not yet recruitingNCT07603557

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyAutoimmune Hemolytic Anemia, Chronic Immune Thrombocytopenia

Start: 2026-08-31End: 2030-05-06Target: 52Updated: 2026-07-09

Phase 3

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Not yet recruitingNCT07335562

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanySystemic Sclerosis

Start: 2027-02-03End: 2030-11-11Target: 92Updated: 2026-09-18